nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

29.04.2021 | Invited Review

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies

verfasst von: Lucas Silva Rodrigues, Giordano Novak Rossi, Juliana Mendes Rocha, Flávia L Osório, José Carlos Bouso, Jaime E. Cecílio Hallak, Rafael G. dos Santos

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Ayahuasca is a hallucinogenic/psychedelic traditionally used for ritual and therapeutic purposes. One such therapeutic use is related to Substance Use Disorders (SUDs). A previous systematic review of preclinical and human studies published until 2016 suggested that ayahuasca and its alkaloids have therapeutic effects in the treatment of SUDs. To conduct an update of this previous review. A systematic review of quantitative studies which analyzed the effects of ayahuasca and its alkaloids on drug use (primary outcome) and other measures (secondary outcomes) related to SUDs was conducted, including articles from 2016 to 2020. Nine studies (four preclinical, five observational) were included in the review. Preclinical studies in rodents reported reductions in amphetamine self-administration and anxiety, and in alcohol- and methylphenidate-induced conditioned place preference. Observational studies among healthy ritual ayahuasca users and patients with SUDs reported reductions in drug use, anxiety, and depression, and increases in quality of life and well-being. We replicated the findings of the previous review suggesting that ayahuasca and its alkaloids have therapeutic effects in the treatment of SUDs. However, translation of preclinical data to humans is limited, observational studies do not allow us to infer causality, and there is a lack of standardization on ayahuasca doses. Although promising, randomized, controlled trials are needed to better elucidate these results. The PROSPERO ID for this study is CRD42020192046.

Nur mit Berechtigung zugänglich

Brandon TH, Vidrine JI, Litvin EB (2007) Relapse and relapse prevention. Annu Rev Clin Psychol 3:257–284. https://doi.org/10.1146/annurev.clinpsy.3.022806.091455CrossRefPubMed

Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annu Rev Psychol 59:29–53. https://doi.org/10.1146/annurev.psych.59.103006.093548CrossRefPubMed

BD 2016 Alcohol and Drug Use Collaborators (2018) The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 5:987–1012. https://doi.org/10.1016/S2215-0366(18)30337-7CrossRef

Lo TW, Yeung JWK, Tam CHL (2020) Substance abuse and public health: a multilevel perspective and multiple responses. Int J Environ Res Public Health 17:2610. https://doi.org/10.3390/ijerph17072610CrossRefPubMedCentral

van Amsterdam J, Nutt D, Phillips L, van den Brink W (2015) European rating of drug harms. J Psychopharmacol 29:655–660. https://doi.org/10.1177/0269881115581980CrossRefPubMed

Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327–1337CrossRefPubMed

Dos Santos RG, Hallak JEC (2019) Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. Epilepsy Behav. https://doi.org/10.1016/j.yebeh.2019.04.053CrossRefPubMed

Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JA, Hallak JE, Ribeiro S, de Araujo DB (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 10:e0118143. https://doi.org/10.1371/journal.pone.0118143CrossRefPubMedPubMedCentral

Rocha JM, Osório FL, Crippa JAS, Bouso JC, Rossi GN, Hallak JEC, Dos Santos RG (2019) Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Ther Adv Psychopharmacol 9:2045125319845774. https://doi.org/10.1177/2045125319845774CrossRefPubMedPubMedCentral

10.

Bogenschutz MP, Forcehimes AA (2017) Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Humanistic Psychol 57:389–414. https://doi.org/10.1177/0022167816673493CrossRef

11.

Krebs TS, Johansen PØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26:994–1002. https://doi.org/10.1177/0269881112439253CrossRefPubMed

12.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT_2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28:983–992. https://doi.org/10.1177/0269881114548296CrossRefPubMedPubMedCentral

13.

Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol 32:756–769. https://doi.org/10.1177/0269881118780612CrossRefPubMed

14.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289–299. https://doi.org/10.1177/0269881114565144CrossRefPubMed

15.

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE (2018) Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Front Pharmacol 9:100. https://doi.org/10.3389/fphar.2018.00100CrossRefPubMedPubMedCentral

16.

Garcia-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7:157–164. https://doi.org/10.2174/1874473708666150107121331CrossRefPubMed

17.

Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW (2020) Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry 10:955. https://doi.org/10.3389/fpsyt.2019.00955CrossRefPubMedPubMedCentral

18.

Lea T, Amada N, Jungaberle H et al (2020) Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology 237:1521–1532. https://doi.org/10.1007/s00213-020-05477-0CrossRefPubMed

19.

Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol 31:841–850. https://doi.org/10.1177/0269881116684335CrossRefPubMedPubMedCentral

20.

Lai HM, Cleary M, Sitharthan T, Hunt GE (2015) Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: a systematic review and meta-analysis. Drug Alcohol Depend 154:1–13. https://doi.org/10.1016/j.drugalcdep.2015.05.031CrossRefPubMed

21.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181–1197. https://doi.org/10.1177/0269881116675513CrossRefPubMedPubMedCentral

22.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165–1180. https://doi.org/10.1177/0269881116675512CrossRefPubMedPubMedCentral

23.

Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627. https://doi.org/10.1016/S2215-0366(16)30065-7CrossRefPubMed

24.

Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry e203285. https://doi.org/10.1001/jamapsychiatry.2020.3285.

25.

Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE (2016) The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol 30:1230–1247. https://doi.org/10.1177/0269881116652578CrossRefPubMed

26.

Dos Santos RG, Osório FL, Crippa JA, Hallak JE (2016) Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry 38:65–72. https://doi.org/10.1590/1516-4446-2015-1701CrossRefPubMedPubMedCentral

27.

Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, Saide OL, Labigalini E, Tacla C, Miranda CT, Strassman RJ, Boone KB (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184:86–94. https://doi.org/10.1097/00005053-199602000-00004CrossRefPubMed

28.

Labate B, dos Santos RG, Anderson B, Mercante M, Barbosa PCR (2010) The treatment and handling of substance dependence with ayahuasca: reflections on current and future research. In: Labate BC, MacRae E (eds) Ayahuasca, ritual and religion in Brazil. Equinox, London and Oakville, pp 205–227

29.

Loizaga-Velder A, Verres R (2014) Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence–qualitative results. J Psychoactive Drugs 46:63–72. https://doi.org/10.1080/02791072.2013.873157CrossRefPubMed

30.

Apud I, Romaní O (2017) Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective. Int J Drug Policy 39:28–36. https://doi.org/10.1016/j.drugpo.2016.07.011CrossRefPubMed

31.

Talin P, Sanabria E (2017) Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from “addiction.” Int J Drug Policy 44:23–30. https://doi.org/10.1016/j.drugpo.2017.02.017CrossRefPubMedPubMedCentral

32.

Nunes AA, Dos Santos RG, Osório FL, Sanches RF, Crippa JA, Hallak JE (2016) Effects of ayahuasca and its alkaloids on drug dependence: a systematic literature review of quantitative studies in animals and humans. J Psychoactive Drugs 48:195–205. https://doi.org/10.1080/02791072.2016.1188225CrossRefPubMed

33.

Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW Jr, Carlson JN (1994) Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 657:14–22. https://doi.org/10.1016/0006-8993(94)90948-2CrossRefPubMed

34.

Aricioglu-Kartal F, Kayir H, Tayfun Uzbay I (2003) Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Life Sci 73:2363–2371. https://doi.org/10.1016/s0024-3205(03)00647-7CrossRefPubMed

35.

Brierley DI, Davidson C (2013) Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. J Psychopharmacol 27:98–108. https://doi.org/10.1177/0269881112463125CrossRefPubMed

36.

Owaisat S, Raffa RB, Rawls SM (2012) In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett 525:12–16. https://doi.org/10.1016/j.neulet.2012.07.052CrossRefPubMedPubMedCentral

37.

Oliveira-Lima AJ, Santos R, Hollais AW, Gerardi-Junior CA, Baldaia MA, Wuo-Silva R, Yokoyama TS, Costa JL, Malpezzi-Marinho EL, Ribeiro-Barbosa PC, Berro LF, Frussa-Filho R, Marinho EA (2015) Effects of ayahuasca on the development of alcohol-induced behavioral sensitization and on a post-sensitization treatment in mice. Physiol Behav 142:28–36. https://doi.org/10.1016/j.physbeh.2015.01.032CrossRefPubMed

38.

Da Silveira DX, Grob CS, de Rios MD, Lopez E, Alonso LK, Tacla C, Doering-Silveira E (2005) Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs 37:129–133. https://doi.org/10.1080/02791072.2005.10399792CrossRefPubMed

39.

Doering-Silveira E, Grob CS, de Rios MD, Lopez E, Alonso LK, Tacla C, Da Silveira DX (2005) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 37:141–144. https://doi.org/10.1080/02791072.2005.10399794CrossRefPubMed

40.

Fábregas JM, González D, Fondevila S, Cutchet M, Fernández X, Barbosa PC, Alcázar-Córcoles MÁ, Barbanoj MJ, Riba J, Bouso JC (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 111:257–261. https://doi.org/10.1016/j.drugalcdep.2010.03.024CrossRefPubMed

41.

Thomas G, Lucas P, Capler NR, Tupper KW, Martin G (2013) Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 6:30–42. https://doi.org/10.2174/15733998113099990003CrossRefPubMed

42.

Fernández X, dos Santos RG, Cutchet M, Fondevila S, González D, Alcázar MÁ, María Fábregas J (2014) Assessment of the psychotherapeutic effects of ritual ayahuasca use on drug dependency: a pilot study. Therap Use Ayahuasca. https://doi.org/10.1007/978-3-642-40426-9_11CrossRef

43.

Jiménez-Garrido DF, Gómez-Sousa M, Ona G, Dos Santos RG, Hallak JEC, Alcázar-Córcoles MÁ, Bouso JC (2020) Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination. Sci Rep 10:4075. https://doi.org/10.1038/s41598-020-61169-xCrossRefPubMedPubMedCentral

44.

Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, Hallak JE (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36:77–81. https://doi.org/10.1097/JCP.0000000000000436CrossRefPubMed

45.

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Osório FL, Sanches R, Dos Santos RG, Tófoli LF, de Oliveira SG, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galvão-Coelho NL, Lobão-Soares B, Hallak JEC, Arcoverde E, Maia-de-Oliveira JP, Araújo DB (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49:655–663. https://doi.org/10.1017/S0033291718001356CrossRefPubMedPubMedCentral

46.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. https://doi.org/10.1186/2046-4053-4-1CrossRefPubMedPubMedCentral

47.

Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. https://doi.org/10.1186/1471-2288-14-43CrossRefPubMedPubMedCentral

48.

Barbosa PC, Strassman RJ, da Silveira DX, Areco K, Hoy R, Pommy J, Thoma R, Bogenschutz M (2016) Psychological and neuropsychological assessment of regular hoasca users. Compr Psychiatry 71:95–105. https://doi.org/10.1016/j.comppsych.2016.09.003CrossRefPubMed

49.

Barbosa PCR, Tófoli LF, Bogenschutz MP, Hoy R, Berro LF, Marinho EAV, Areco KN, Winkelman MJ (2018) Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. Front Psychiatry 9:136. https://doi.org/10.3389/fpsyt.2018.00136CrossRefPubMedPubMedCentral

50.

Berlowitz I, Walt H, Ghasarian C, Mendive F, Martin-Soelch C (2019) Short-term treatment effects of a substance use disorder therapy involving traditional amazonian medicine. J Psychoactive Drugs 51:323–334. https://doi.org/10.1080/02791072.2019.1607956CrossRefPubMed

51.

Cata-Preta EG, Serra YA, Moreira-Junior EDC, Reis HS, Kisaki ND, Libarino-Santos M, Silva RRR, Barros-Santos T, Santos LC, Barbosa PCR, Costa JL, Oliveira-Lima AJ, Berro LF, Marinho EAV (2018) Ayahuasca and Its DMT- and β-carbolines—containing ingredients block the expression of alcohol-induced conditioned place preference in mice: role of the treatment environment. Front Pharmacol 9:561. https://doi.org/10.3389/fphar.2018.00561CrossRefPubMedPubMedCentral

52.

Giovannetti C, Garcia Arce S, Rush B, Mendive F (2020) Pilot evaluation of a residential drug addiction treatment combining traditional amazonian medicine, ayahuasca and psychotherapy on depression and anxiety. J Psychoactive Drugs. https://doi.org/10.1080/02791072.2020.1789247CrossRefPubMed

53.

Lawn W, Hallak JE, Crippa JA, Dos Santos R, Porffy L, Barratt MJ, Ferris JA, Winstock AR, Morgan CJA (2017) Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep 7:15201. https://doi.org/10.1038/s41598-017-14700-6CrossRefPubMedPubMedCentral

54.

Nolli LM, de Oliveira DGR, Alves SS, von Zuben MV, Pic-Taylor A, Mortari MR, Caldas ED (2019) Effects of the hallucinogenic beverage ayahuasca on voluntary alcohol intake by rats and on cFos expression in brain areas relevant to drug addiction. Alcohol 84:67–75. https://doi.org/10.1016/j.alcohol.2019.10.005CrossRefPubMed

55.

Reis HS, Rodrigues IRS, Anjos-Santos A, Libarino-Santos M, Serra YA, Cata-Preta EG, Oliveira-Campos D, Kisaki ND, Barros-Santos T, Yokoyama TS, Cruz FC, Oliveira-Lima AJ, Barbosa PCR, Berro LF, Marinho EAV (2020) Ayahuasca blocks the reinstatement of methylphenidate-induced conditioned place preference in mice: behavioral and brain Fos expression evaluations. Psychopharmacology 237:3269–3281. https://doi.org/10.1007/s00213-020-05609-6CrossRefPubMed

56.

Godinho AF, Silva MC, Kawashima JD et al (2017) Ayahuasca modifies amphetamine self ingestion and modifies anxiety and locomotor activity in adolescent rats. Electron J Biol 13:2

57.

Bouso JC, Fábregas JM, Antonijoan RM, Rodríguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology 230:415–424. https://doi.org/10.1007/s00213-013-3167-9CrossRefPubMed

58.

Howell LL, Cunningham KA (2015) Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev 67:176–197. https://doi.org/10.1124/pr.114.009514CrossRefPubMedPubMedCentral

59.

Bouso JC, Dos Santos RG, Alcázar-Córcoles MÁ, Hallak JEC (2018) Serotonergic psychedelics and personality: a systematic review of contemporary research. Neurosci Biobehav Rev 87:118–132. https://doi.org/10.1016/j.neubiorev.2018.02.004CrossRefPubMed

60.

Alper K, Dong B, Shah R, Sershen H, Vinod KY (2018) LSD Administered as a single dose reduces alcohol consumption in C57BL/6J mice. Front Pharmacol 9:994. https://doi.org/10.3389/fphar.2018.00994CrossRefPubMedPubMedCentral

61.

Meinhardt MW, Güngör C, Skorodumov I, Mertens LJ, Spanagel R (2020) Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. Neuropsychopharmacology 45:1316–1322. https://doi.org/10.1038/s41386-020-0694-zCrossRefPubMedPubMedCentral

62.

Maurel S, De Vry J, Schreiber R (1999) 5-HT receptor ligands differentially affect operant oral self-administration of alcohol in the rat. Eur J Pharmacol 370:217–223. https://doi.org/10.1016/s0014-2999(99)00125-9CrossRefPubMed

63.

Vargas-Perez H, Grieder TE, Ting-A-Kee R, Maal-Bared G, Chwalek M, van der Kooy D (2017) A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents. Eur J Neurosci 45:1410–1417. https://doi.org/10.1111/ejn.13572CrossRefPubMed

64.

Oppong-Damoah A, Curry KE, Blough BE, Rice KC, Murnane KS (2019) Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on alcohol consumption and place conditioning in male mice. Psychopharmacology 236:3567–3578. https://doi.org/10.1007/s00213-019-05328-7CrossRefPubMedPubMedCentral

65.

Martin DA, Gyawali U, Calu DJ (2020) Effects of 5-HT_2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats. Addict Biol e12926. https://doi.org/10.1111/adb.12926.

66.

Ona G, Kohek M, Massaguer T, Gomariz A, Jiménez DF, Dos Santos RG et al (2019) Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs 51:135–145CrossRefPubMed

Titel: Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies
verfasst von: Lucas Silva Rodrigues
Giordano Novak Rossi
Juliana Mendes Rocha
Flávia L Osório
José Carlos Bouso
Jaime E. Cecílio Hallak
Rafael G. dos Santos
Publikationsdatum: 29.04.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 4/2022
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-021-01267-7

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the “Parma Early Psychosis” program

Functional and clinical outcomes of FMRI-based neurofeedback training in patients with alcohol dependence: a pilot study

Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals

An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s